Coutré, Steven E.Barrientos, Jacqueline C.Brown, Jenniferde Vos, SvenFurman, Richard R.Keating, Michael J.Li, DanielO’Brien, Susan M.Pagel, John M.Poleski, Martin H.Sharman, Jeff P.Yao, Nai-ShunZelenetz, Andrew D.2016-03-012015Coutré, S. E., J. C. Barrientos, J. R. Brown, S. de Vos, R. R. Furman, M. J. Keating, D. Li, et al. 2015. “Management of adverse events associated with idelalisib treatment: expert panel opinion.” Leukemia & Lymphoma 56 (10): 2779-2786. doi:10.3109/10428194.2015.1022770. http://dx.doi.org/10.3109/10428194.2015.1022770.1042-8194http://nrs.harvard.edu/urn-3:HUL.InstRepos:25658389Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. An expert panel was convened to review the pathology of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy. This article provides an overview of idelalisib TEAEs reported in clinical trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis. For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or intravenous steroid therapy.en-USReviewIdelalisibphosphatidylinositol 3-kinase delta (PI3Kδ) inhibitordiarrheacolitistransaminitispneumonitisJournal Article2016-03-0110.3109/10428194.2015.1022770